IOVA Iovance Biotherapeutics, Inc.: Projected Price to Earnings

IOVA (Iovance Biotherapeutics) - company brandmark

Iovance Biotherapeutics focuses on independent product launches, limiting partnerships strictly to joint testing. The company's forward P/E valuation shows local growth, with the metric recorded at 0.00. Breakthrough treatments for solid tumors using the patient's own cells are combined with strict adherence to bioethics and the minimization of the carbon footprint during drug production.

iovance.com - IOVA Future Price to Earnings Multiple (period 07/04/2022 - 11/16/2026)

Metric breakdowns and analytics for iovance.com (IOVA)

Fundamental company analysis:Iovance Biotherapeutics Inc IOVA
Signature product of Iovance Biotherapeutics

Investors utilize multiples to verify the fair value of assets and assess risks. The forward P/E ratio of the company reflects the relationship between the market price and expected net income, allowing for the discounting of future cash flows. This chart captures shifts in market consensus between quarterly reports. For Iovance Biotherapeutics (IOVA), this indicator measures the market's willingness to pay for the commercialization of TIL therapy and insurance company reimbursements. A decline in this ratio alongside earnings growth confirms the fundamental resilience of the business.

Analysis of competing companies

Forward P/E Multiple IBRX|Immunocore Holdings plc (IMCR) - Forward Price to Earnings Multiple|Janux Therapeutics Inc - Projected Price to Earnings|Arcus Biosciences (RCUS) - Projected Price to Earnings Ratio|ZYME: Projected Price to Earnings|Future Price to Earnings Multiple TNGX (Tango Therapeutics, Inc.)|IMTX: Forward P/E Multiple|XNCR - Market Cap to Projected Earnings|Future Price to Earnings compasstherapeutics.com|Projected Price to Earnings replimune.com (REPL)|Future Price to Earnings Lyell (LYEL)|Projected Price to Earnings Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Projected Price to Earnings|Forward P/E Multiple Compugen Ltd. CGEN|IOBT - Future Price to Earnings|STRO (sutrobio.com) - Price to Future Earnings Ratio|MiNK Therapeutics, Inc (INKT) - Future Price to Earnings|Projected Price to Earnings Ratio Werewolf Therapeutics (HOWL)|Projected Price to Earnings IMMX|ALXO - Forward Price to Earnings Multiple|Forward P/E Multiple CUE|Market Cap to Future Earnings Ratio PDSB|Forward P/E Multiple SONN (Sonnet BioTherapeutics)|Future Price to Earnings Multiple MAIA|liminatuspharma.com - Forward P/E Multiple|Projected Price to Earnings Ratio LAVA Therapeutics|NextCure, Inc. (NXTC) - Future Price to Earnings|Leap Therapeutics Inc - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple